Antimetastatic Role of Smad4 Signaling in Colorectal Cancer

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2009 Nov 14

PMID 19909744

Citations 105

Authors

Bixiang Zhang

Sunil K Halder

Nilesh D Kashikar

Yong-Jig Cho

Arunima Datta

D Lee Gorden

Pran K Datta

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Transforming growth factor (TGF)-beta signaling occurs through Smads 2/3/4, which translocate to the nucleus to regulate transcription; TGF-beta has tumor-suppressive effects in some tumor models and pro-metastatic effects in others. In patients with colorectal cancer (CRC), mutations or reduced levels of Smad4 have been correlated with reduced survival. However, the function of Smad signaling and the effects of TGF-beta-receptor kinase inhibitors have not been analyzed during CRC metastasis. We investigated the role of TGF-beta/Smad signaling in CRC progression.

Methods: We evaluated the role of TGF-beta/Smad signaling on cell proliferation, migration, invasion, tumorigenicity, and metastasis in Smad4-null colon carcinoma cell lines (MC38 and SW620) and in those that transgenically express Smad4. We also determined the effects of a TGF-beta-receptor kinase inhibitor (LY2109761) in CRC tumor progression and metastasis in mice.

Results: TGF-beta induced migration/invasion, tumorigenicity, and metastasis of Smad4-null MC38 and SW620 cells; incubation with LY2109761 reversed these effects. In mice, LY2109761 blocked metastasis of CRC cells to liver, inducing cancer cell expression of E-cadherin and reducing the expression of the tumorigenic proteins matrix metalloproteinase-9, nm23, urokinase plasminogen activator, and cyclooxygenase-2. Transgenic expression of Smad4 significantly reduced the oncogenic potential of MC38 and SW620 cells; in these transgenic cells, TGF-beta had tumor suppressor, rather than tumorigenic, effects.

Conclusions: TGF-beta/Smad signaling suppresses progression and metastasis of CRC cells and tumors in mice. Loss of Smad4 might underlie the functional shift of TGF-beta from a tumor suppressor to a tumor promoter; inhibitors of TGF-beta signaling might be developed as CRC therapeutics.

Citing Articles

The Lyn/RUVBL1 Complex Promotes Colorectal Cancer Liver Metastasis by Regulating Arachidonic Acid Metabolism Through Chromatin Remodeling.

Zhang Z, Gao Y, Qian Y, Wei B, Jiang K, Sun Z Adv Sci (Weinh). 2024; 12(5):e2406562.

PMID: 39665272 PMC: 11792055. DOI: 10.1002/advs.202406562.

In Vitro Cytotoxicity of Fluorinated Quaternary Ammonium Salts in Colorectal Cancer Cells and In Silico Pharmacology.

Aponte A, Ospina V, Pulido S, Rios-Vasquez L, Jaramillo L, Muneton Pena C Adv Pharmacol Pharm Sci. 2024; 2024:2671547.

PMID: 39512304 PMC: 11540889. DOI: 10.1155/2024/2671547.

TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance.

Johansen A, Forsythe S, McGrath C, Barker G, Jimenez H, Paluri R Clin Cancer Res. 2024; 30(17):3676-3687.

PMID: 38916900 PMC: 11371528. DOI: 10.1158/1078-0432.CCR-24-0468.

Comprehensive analysis of the role of ubiquitin-specific peptidases in colorectal cancer: A systematic review.

Al-Balushi E, Al Marzouqi A, Tavoosi S, Baghsheikhi A, Sadri A, Sharifi Aliabadi L World J Gastrointest Oncol. 2024; 16(1):197-213.

PMID: 38292842 PMC: 10824112. DOI: 10.4251/wjgo.v16.i1.197.

In Vitro Organoid-Based Assays Reveal SMAD4 Tumor-Suppressive Mechanisms for Serrated Colorectal Cancer Invasion.

Tong K, Bandari M, Carrick J, Zenkevich A, Kothari O, Shamshad E Cancers (Basel). 2023; 15(24).

PMID: 38136364 PMC: 10742020. DOI: 10.3390/cancers15245820.

References

Fransvea E, Angelotti U, Antonaci S, Giannelli G . Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology. 2008; 47(5):1557-66. DOI: 10.1002/hep.22201. View

Ismail N, Kaur G, Hashim H, Hassan M . Nuclear localization and intensity of staining of nm23 protein is useful marker for breast cancer progression. Cancer Cell Int. 2008; 8:6. PMC: 2396598. DOI: 10.1186/1475-2867-8-6. View

Zou M, Shi Y, Al-Sedairy S, Farid N . High levels of Nm23 gene expression in advanced stage of thyroid carcinomas. Br J Cancer. 1993; 68(2):385-8. PMC: 1968576. DOI: 10.1038/bjc.1993.345. View

Calonge M, Massague J . Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem. 1999; 274(47):33637-43. DOI: 10.1074/jbc.274.47.33637. View

Melisi D, Ishiyama S, Sclabas G, Fleming J, Xia Q, Tortora G . LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008; 7(4):829-40. PMC: 3088432. DOI: 10.1158/1535-7163.MCT-07-0337. View

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

Sarris M, Lee C . nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver. Eur J Surg Oncol. 2001; 27(2):170-4. DOI: 10.1053/ejso.2000.1070. View

Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M . Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 1999; 18(20):3098-103. DOI: 10.1038/sj.onc.1202642. View

Kang Y, He W, Tulley S, Gupta G, Serganova I, Chen C . Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A. 2005; 102(39):13909-14. PMC: 1236573. DOI: 10.1073/pnas.0506517102. View

10.

Behrens J . Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev. 1999; 18(1):15-30. DOI: 10.1023/a:1006200102166. View

11.

Berger J, Vander Griend D, Robinson V, Hickson J, Rinker-Schaeffer C . Metastasis suppressor genes: from gene identification to protein function and regulation. Cancer Biol Ther. 2005; 4(8):805-12. DOI: 10.4161/cbt.4.8.1865. View

12.

Javelaud D, Mohammad K, McKenna C, Fournier P, Luciani F, Niewolna M . Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res. 2007; 67(5):2317-24. DOI: 10.1158/0008-5472.CAN-06-3950. View

13.

Halder S, Beauchamp R, Datta P . A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005; 7(5):509-21. PMC: 1501161. DOI: 10.1593/neo.04640. View

14.

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

15.

Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T . Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst. 2005; 97(23):1734-46. DOI: 10.1093/jnci/dji399. View

16.

Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S . Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res. 2006; 12(14 Pt 1):4315-30. DOI: 10.1158/1078-0432.CCR-06-0162. View

17.

Bandyopadhyay A, Agyin J, Wang L, Tang Y, Lei X, Story B . Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 2006; 66(13):6714-21. DOI: 10.1158/0008-5472.CAN-05-3565. View

18.

Halder S, Rachakonda G, Deane N, Datta P . Smad7 induces hepatic metastasis in colorectal cancer. Br J Cancer. 2008; 99(6):957-65. PMC: 2538763. DOI: 10.1038/sj.bjc.6604562. View

19.

Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin J . SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 2005; 11(7):2606-11. DOI: 10.1158/1078-0432.CCR-04-1458. View

20.

Losi L, Bouzourene H, Benhattar J . Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep. 2007; 17(5):1095-9. View